Trulicity History & Development: How Dulaglutide Was Discovered, Engineered, and Approved

The Scientific Roots: Why Researchers Chased GLP-1 in the First Place

The story of dulaglutide begins not with Eli Lilly but with a Gila monster. Exendin-4, a peptide isolated from the salivary glands of Heloderma suspectum in the early 1990s by endocrinologist John Eng, shared roughly 53% sequence homology with human glucagon-like peptide-1 (GLP-1) yet resisted degradation by dipeptidyl peptidase-4 (DPP-4). That discovery redirected an entire field toward GLP-1 receptor agonism as a mechanism to lower postprandial glucose, reduce appetite, and potentially protect beta-cell mass simultaneously. Eng's original characterization was published in 1992.

The Problem with Native GLP-1

Native GLP-1 has a plasma half-life of less than two minutes. DPP-4 cleaves the N-terminal dipeptide His-Ala almost instantly after secretion from L-cells of the distal intestine. Subcutaneous delivery of native GLP-1 required continuous infusion to sustain meaningful receptor activation. That ruled it out commercially and clinically. The pharmacological challenge, then, was to retain GLP-1's receptor-binding fidelity while dramatically slowing clearance.

Early GLP-1 Analogs and the Half-Life Problem

Exenatide (Byetta), the first approved GLP-1 receptor agonist, reached the market in 2005. Its twice-daily dosing reflected a half-life of only 2.4 hours. Liraglutide (Victoza), approved by the FDA in January 2010, extended this to roughly 13 hours through fatty-acid acylation that promoted albumin binding, enabling once-daily dosing. But the field was already asking the next question: could a GLP-1 analog be engineered for once-weekly subcutaneous dosing without sacrificing tolerability? The pharmacology of liraglutide is summarized in FDA labeling.

Eli Lilly's Engineering Strategy: The Fc-Fusion Approach

Lilly's research team took a fundamentally different path than Novo Nordisk's acylation approach. Rather than attaching a fatty acid, they fused a modified GLP-1 peptide to the Fc region of human immunoglobulin G4 (IgG4). This design choice governed almost every property the final molecule would have.

How the Fc-Fusion Extends Half-Life

IgG4 antibodies are recycled through the neonatal Fc receptor (FcRn) pathway rather than degraded in lysosomes. When dulaglutide binds FcRn in endosomes, it is trafficked back to the cell surface and released into circulation. This salvage mechanism, combined with the large hydrodynamic radius of the roughly 60-kilodalton homodimer, reduces renal clearance and yields a half-life of approximately 4.7 days in humans. A detailed pharmacokinetic analysis across populations was published in Clinical Pharmacokinetics.

Sequence Modifications to the GLP-1 Peptide

The GLP-1(7-37) peptide itself required two point mutations before it could be safely fused to the Fc region. Alanine at position 8 was replaced with aminoisobutyric acid (Aib) to block DPP-4 cleavage. Glycine at position 22 was substituted to reduce receptor-independent aggregation. A small synthetic linker then tethers two copies of this modified peptide to the Fc homodimer, so each dulaglutide molecule presents two GLP-1 binding domains. Pre-clinical receptor binding studies confirmed that these changes preserved full agonist activity at the GLP-1 receptor. Structural characterization of dulaglutide's peptide-Fc linkage was described in Bioconjugate Chemistry.

Immunogenicity Considerations

Using human IgG4 rather than a foreign-protein scaffold was a deliberate immunogenicity-reduction strategy. Phase III anti-drug antibody incidence rates in the AWARD program were low: across AWARD-1 through AWARD-5, detectable antibodies were found in approximately 1.6% of participants receiving dulaglutide 1.5 mg, and neutralizing antibodies in fewer than 1%. No antibody-related efficacy loss or hypersensitivity cluster was observed.

Preclinical Development and Phase I Findings

Before large phase III trials, Lilly conducted preclinical studies in Zucker diabetic fatty rats and cynomolgus monkeys to characterize glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and weight effects. These animal data also showed dose-dependent beta-cell preservation as measured by islet morphometry, though the clinical relevance of that finding in humans remains a topic of ongoing research.

Phase I trials in healthy volunteers confirmed that a single subcutaneous dose of dulaglutide produced GLP-1 receptor activation lasting well beyond seven days, with the pharmacodynamic tail supporting once-weekly dosing. Single-dose and multiple-dose studies established the 0.75 mg and 1.5 mg doses as the range where glycemic effect plateaued without unacceptable nausea rates. Phase I pharmacodynamic results were summarized in the FDA clinical pharmacology review.

The AWARD Trial Program: Phase III Evidence

Lilly designed eight key phase III trials under the AWARD (Assessment of Weekly Administration of LY2189265 in Diabetes) program. Together they enrolled more than 6,000 participants and compared dulaglutide against placebo, metformin monotherapy, exenatide twice daily, sitagliptin, insulin glargine, and insulin lispro.

AWARD-1: Establishing Superiority Over Exenatide

AWARD-1 (N=978) compared dulaglutide 1.5 mg, dulaglutide 0.75 mg, exenatide 10 mcg twice daily, and placebo as add-on to metformin plus pioglitazone over 52 weeks. At 26 weeks, dulaglutide 1.5 mg reduced HbA1c by 1.51% from a baseline of 8.1%, compared with 0.99% for exenatide and 0.46% for placebo. The between-group difference for dulaglutide 1.5 mg versus exenatide was statistically significant (P<0.001). AWARD-1 results were published in Diabetes Care (2014).

AWARD-5: Superiority Over Sitagliptin

AWARD-5 (N=1,098) pitted dulaglutide against sitagliptin 100 mg daily over 104 weeks in patients on metformin. At 52 weeks, dulaglutide 1.5 mg produced a 1.10% HbA1c reduction versus 0.39% for sitagliptin (P<0.001). Body weight fell by 3.03 kg with dulaglutide 1.5 mg compared with 1.36 kg for sitagliptin. AWARD-5 was published in Diabetes Care (2014).

AWARD-6: Head-to-Head Against Liraglutide

AWARD-6 (N=599) is the only direct head-to-head trial between dulaglutide and liraglutide. At 26 weeks, dulaglutide 1.5 mg once weekly reduced HbA1c by 1.42% versus 1.36% for liraglutide 1.8 mg once daily (difference 0.06%, 95% CI −0.19 to 0.07), meeting the pre-specified non-inferiority margin of 0.4%. Body weight reduction was slightly greater with liraglutide (−3.61 kg vs. −2.90 kg), but gastrointestinal adverse event rates were comparable. AWARD-6 was published in Diabetes Care (2014).

The AWARD trials collectively demonstrated that the molecule Lilly had engineered through Fc-fusion technology could match or beat existing once-daily and twice-daily GLP-1 agents in glycemic control while offering the convenience of once-weekly dosing and no requirement for reconstitution. That convenience argument would prove central to the drug's commercial success and real-world adherence data.

FDA Approval: September 2014

The FDA approved dulaglutide on September 18, 2014 under the brand name Trulicity, initially for adults with type 2 diabetes as an adjunct to diet and exercise. The approval covered two doses: 0.75 mg and 1.5 mg administered subcutaneously once weekly via a single-dose autoinjector pen that required no reconstitution and no needle attachment by the patient.

The agency's review noted the integrated AWARD efficacy data alongside a thorough cardiovascular risk evaluation. At the time of approval, the FDA required Lilly to conduct a dedicated cardiovascular outcomes trial, consistent with the 2008 FDA guidance requiring all new type 2 diabetes therapies to demonstrate cardiovascular non-inferiority. The FDA approval package is publicly available.

The single-dose autoinjector design deserves specific credit for the product's uptake. A human factors study showed that patients with no prior injection experience could correctly self-administer using the device after watching a brief demonstration, with a success rate above 97% in simulated-use testing.

The REWIND Trial: A Cardiovascular Landmark

The Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial was the largest and longest cardiovascular outcomes trial ever conducted with a GLP-1 receptor agonist at the time of its publication.

Design and Population

REWIND enrolled 9,901 adults with type 2 diabetes at 371 sites across 24 countries. Unlike LEADER (liraglutide) and SUSTAIN-6 (semaglutide), which enrolled populations with very high baseline cardiovascular risk (majority with established cardiovascular disease), REWIND was more inclusive. Only 31.5% of participants had established cardiovascular disease at baseline; the remainder had cardiovascular risk factors only. Median follow-up was 5.4 years, considerably longer than most cardiovascular outcomes trials in diabetes. REWIND was published in The Lancet (2019).

Primary Outcome Results

The primary composite endpoint was first occurrence of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. Dulaglutide 1.5 mg reduced this composite by 12% relative to placebo (HR 0.88, 95% CI 0.79 to 0.99, P=0.026). The absolute risk reduction was 1.4 percentage points over the 5.4-year follow-up (13.4% vs. 14.8%). The number needed to treat for 5.4 years to prevent one MACE event was approximately 71.

The stroke component drove much of the signal: nonfatal stroke was reduced by 24% (HR 0.76, 95% CI 0.61 to 0.95). Nonfatal MI showed a non-significant trend (HR 0.96, 95% CI 0.79 to 1.16). Cardiovascular death was not significantly reduced on its own.

Secondary Findings: Kidney and Cognition

A pre-specified renal composite (sustained 40% decline in eGFR, macroalbuminuria, or renal replacement therapy) was reduced by 15% with dulaglutide (HR 0.85, 95% CI 0.77 to 0.93, P<0.001). A cognition sub-study using the Montreal Cognitive Assessment found a smaller decline in REWIND participants randomized to dulaglutide over 5 years, though this was exploratory and requires confirmation in dedicated trials. The renal sub-analysis of REWIND was published in The Lancet Diabetes and Endocrinology.

Regulatory Impact of REWIND

The FDA approved an updated label in 2020, adding a cardiovascular risk-reduction indication for adults with type 2 diabetes who also have established cardiovascular disease or multiple cardiovascular risk factors. The American Diabetes Association (ADA) Standards of Medical Care incorporated this evidence: the 2023 guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred agents in patients with atherosclerotic cardiovascular disease or high cardiovascular risk, independent of baseline HbA1c. The guideline language states: "In patients with type 2 diabetes and established CVD or high/very high CVD risk, a GLP-1 receptor agonist with demonstrated CVD benefit is recommended." ADA Standards of Medical Care 2023.

Dose Expansion: 3.0 mg and 4.5 mg

In January 2020, concurrent with the cardiovascular label update, the FDA approved two higher doses of dulaglutide: 3.0 mg and 4.5 mg once weekly. These were supported by the AWARD-11 trial (N=1,842), which showed that dulaglutide 4.5 mg reduced HbA1c by 1.6% from a mean baseline of 8.6% at 36 weeks, versus 1.3% for the 1.5 mg dose (P<0.001). Body weight decreased by 4.7 kg at 4.5 mg versus 3.0 kg at 1.5 mg. AWARD-11 was published in The Lancet Diabetes and Endocrinology (2021).

The higher doses were positioned to help patients who needed more glycemic control without adding a second agent, and to improve weight outcomes, though dulaglutide's weight effect at 4.5 mg remains more modest than semaglutide 2.4 mg (Ozempic/Wegovy) or tirzepatide (Mounjaro), which reduces body weight by 22.5% at 72 weeks in the SURMOUNT-1 trial.

Mechanism of Action: How Dulaglutide Works at the Receptor Level

Understanding how dulaglutide works requires tracing the GLP-1 receptor's downstream signaling cascade, not just the glucose-lowering effect.

GLP-1 Receptor Binding and cAMP Signaling

The GLP-1 receptor is a class B G-protein-coupled receptor (GPCR) expressed primarily on pancreatic beta cells but also on alpha cells, cardiac myocytes, renal tubular cells, and neurons of the vagus nerve and central nervous system. When dulaglutide binds, it activates Gs-coupled adenylyl cyclase, raising intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac2), both of which potentiate glucose-stimulated insulin secretion. This glucose-dependency is what distinguishes GLP-1 receptor agonists from sulfonylureas: below approximately 70 mg/dL plasma glucose, the incretin effect weakens substantially, limiting hypoglycemia risk.

Glucagon Suppression

Dulaglutide suppresses glucagon secretion from alpha cells in a glucose-dependent fashion. This effect is meaningful postprandially, when excess glucagon in type 2 diabetes contributes to hepatic glucose output. A meta-analysis of GLP-1 receptor agonist trials found a mean reduction in fasting glucagon of approximately 10 to 15 pmol/L compared with placebo. Glucagon suppression mechanisms are reviewed in Endocrine Reviews.

Gastric Emptying Delay and Appetite Effects

GLP-1 receptors on the vagus nerve and the dorsal vagal complex slow gastric emptying. This contributes to postprandial glucose reduction but also to the nausea and vomiting that affect approximately 10 to 15% of patients, particularly in the first four to eight weeks of therapy. Central GLP-1 receptor activation in the hypothalamus and area postrema reduces appetite signals, explaining the modest but consistent weight loss seen across AWARD trials (mean of 1.4 to 3.0 kg at standard doses).

Cardiovascular Mechanisms Beyond Glucose Lowering

The 12% MACE reduction in REWIND was only partially attributable to HbA1c differences between groups (between-group difference at 26 months was just 0.61%). Animal data and small human studies suggest direct GLP-1 receptor-mediated effects on cardiac function including reduced cardiac oxidative stress, anti-inflammatory signaling via reduced NF-kB activation, and endothelium-dependent vasodilation. Whether these are causal in humans or epiphenomenal remains debated. Cardiovascular mechanisms of GLP-1 receptor agonists are reviewed in Circulation.

Pediatric and Expanded Population Studies

In June 2023, the FDA approved dulaglutide for use in pediatric patients aged 10 and older with type 2 diabetes, based on the AWARD-PEDS trial (N=154). At 26 weeks, dulaglutide 0.75 mg reduced HbA1c by 0.6% compared with placebo-adjusted change of +0.8%, a treatment difference of 1.4% (P<0.001). Dulaglutide 1.5 mg showed a 1.6% treatment difference. This expanded Trulicity's eligible population to adolescents, a group with rapidly increasing type 2 diabetes prevalence. AWARD-PEDS results were published in The New England Journal of Medicine (2022).

Where Dulaglutide Fits in 2025: Competition and Clinical Positioning

The GLP-1 receptor agonist market changed sharply after semaglutide's approval for weight management (Wegovy, 2021) and after tirzepatide's approvals for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023). Semaglutide 2.4 mg produced 14.9% mean body weight loss in STEP-1 (N=1,961) at 68 weeks versus 2.4% with placebo. STEP-1 was published in The New England Journal of Medicine (2021).

Dulaglutide offers a more modest weight effect but has a longer, better-characterized cardiovascular outcomes dataset (5.4 years in REWIND) than most competitors, a well-established tolerability profile, and a simple delivery device with no needle handling. For patients whose primary goal is cardiovascular risk reduction rather than substantial weight loss, and who value ease of administration, dulaglutide retains a clinically defensible position.

The Endocrine Society 2023 clinical practice guideline on type 2 diabetes states: "For patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk, we recommend GLP-1 receptor agonists with proven cardiovascular benefit." Dulaglutide is one of three agents explicitly named alongside liraglutide and semaglutide as having that evidence. Endocrine Society Guidelines 2023.